Abhirami Hallock1, Olga Vujovic, Edward Yu. 1. Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, Ontario.
Abstract
BACKGROUND: Malignant melanoma is regarded to be radiation resistant. A case of recurrent malignant melanoma with in-transit metastasis treated with short-course, high-fraction palliative radiation is presented to illustrate the effectiveness of radiotherapy. METHOD: An 80-year-old woman initially treated surgically for a primary malignant melanoma of the left lower leg presented with multiple in-transit metastases. Palliative radiation was offered to treat two fungating in-transit masses that were resistant to treatments of isolated limb infusion and intralesional interleukin-2. RESULTS: Treatment consisted of short-course, high-fraction radiation with 800 cGy fractions given over three weeks on days 0, 7 and 21, for a total dose of 2400 cGy. She experienced a complete response that was maintained for six months. CONCLUSIONS: Radiation is an effective treatment option for palliation of recurrent malignant melanoma. Complete response is possible even with short-course, high-fraction radiation.
BACKGROUND:Malignant melanoma is regarded to be radiation resistant. A case of recurrent malignant melanoma with in-transit metastasis treated with short-course, high-fraction palliative radiation is presented to illustrate the effectiveness of radiotherapy. METHOD: An 80-year-old woman initially treated surgically for a primary malignant melanoma of the left lower leg presented with multiple in-transit metastases. Palliative radiation was offered to treat two fungating in-transit masses that were resistant to treatments of isolated limb infusion and intralesional interleukin-2. RESULTS: Treatment consisted of short-course, high-fraction radiation with 800 cGy fractions given over three weeks on days 0, 7 and 21, for a total dose of 2400 cGy. She experienced a complete response that was maintained for six months. CONCLUSIONS: Radiation is an effective treatment option for palliation of recurrent malignant melanoma. Complete response is possible even with short-course, high-fraction radiation.
Authors: K R Trott; H von Lieven; J Kummermehr; D Skopal; S Lukacs; O Braun-Falco; A M Kellerer Journal: Int J Radiat Oncol Biol Phys Date: 1981-01 Impact factor: 7.038
Authors: M H Seegenschmiedt; L Keilholz; A Altendorf-Hofmann; A Urban; H Schell; W Hohenberger; R Sauer Journal: Int J Radiat Oncol Biol Phys Date: 1999-06-01 Impact factor: 7.038
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: W T Sause; J S Cooper; S Rush; C T Ago; D Cosmatos; C T Coughlin; N JanJan; J Lipsett Journal: Int J Radiat Oncol Biol Phys Date: 1991-03 Impact factor: 7.038